A consequence of the use of antibiotics is the development of antibiotic resistance amongst pathogens. In respiratory tract infections the emergence of resistant organisms has necessitated changes in antibiotic policy over the past two decades. In the UK the prevalence of antibiotic resistant respiratory pathogens is lower than in other countries. Nevertheless there is concern for the future. The current state of antibiotic resistance in common acute respiratory pathogens is reviewed in this editorial.
Streptococcus pneumoniae S pneumoniae is the pathogen most commonly implicated in lower respiratory tract infections. It is usually susceptible to penicillins which bind to penicillin binding proteins (PBPs) and inhibit the synthesis of peptidoglycan, a component of the bacterial cell wall. Resistance to penicillins can arise through possession of beta-lactamases, which digest the antibiotic, or alterations in PBPs, the latter being responsible for the resistance of Spneumoniae to penicillins. There are several PBPs, each with a different affinity for penicillins. The has been the occurrence of strains resistant to more than one antibiotic.
The development of resistance reflects the local intensity ofpenicillin usage. In Spain Baquero et al have found a very good temporal correlation between the rising prevalence of resistant isolates and increasing consumption of penicillins.5 Furthermore, the regional variation in penicillin consumption in Spain is also paralleled by the prevalence rate of resistant isolates. Penicillin resistant strains can also be imported from countries with a high prevalence. In Iceland penicillin resistant pneumococci did not exist before 1988. In the subsequent four years they appeared for the first time and the prevalence rate rose dramatically to 17%. Most of the isolates were of one serotype (6B), had the same pattem ofmultiple resistance, and genetic analysis suggested that they arose from one clone. 6 In a study of 431 isolates of S pneumoniae 0 9% were resistant to the second generation cephalosporin cefaclor. '6 Pneumococcal resistance to a number of other antibiotics is well described including erythromycin, tetracycline, chloramphenicol, and co-trimoxazole.'7 Resistance rates for these antibiotics have fluctuated with time and reflect changing patterns of antibiotic usage. In the UK erythromycin resistance currently occurs in 6-5% and tetracycline resistance in 8&1% of isolates.'6 Of major concern is the occurrence of multiply resistant pneumococci which limits therapeutic options. In Barcelona 70% of penicillin resistant pneumococci are also resistant to non-beta-lactam antibiotics.3 This represents a significant proportion of all isolates as the overall prevalence of penicillin resistance in Barcelona is 40%. The most common multiple resistance pattern identified there involves combined resistance to penicillins, tetracycline, chloramphenicol, and co-trimoxazole. In South Africa pneumococcal resistance to two or more antibiotics accounts for about 2% of all pneumococcal isolates. In the UK multiple resistance occurs but is still rare.
Haemophilus influenzae H influenzae accounts for almost half the isolates from sputum samples of patients with exacerbations of chronic obstructive airways disease'8 and about 5% of isolates from patients with community acquired pneumonia. Before the 1970s H influenzae was uniformly sensitive to ampicillin, but since this time resistance to ampicillin and other antibiotics has arisen.'9 The major mechanism of resistance to ampicillin is the production of a beta-lactamase, principally TEM-1. However, some isolates are resistant to antibiotics containing a beta-lactamase inhibitor and the mechanism of resistance in these is altered PBP binding. In addition to resistance to ampicillin, resistance to chloramphenicol, co-trimoxazole, tetracycline, erythromycin, and rifampicin has been described. Resistance to chloramphenicol is due to the presence of the inactivating enzyme chloramphenicol acetyl transferase (CAT), and resistance to trimethoprim is due to increased production of dihydrofolate reductase. The genes for beta-lactamase and chloramphenicol resistance are present on plasmids and can therefore be exchanged between bacteria.
Surveys of the prevalence of resistant H influenzae have been performed in several countries. In North America about 20% of isolates are beta-lactamase producers. '9 In Europe a survey of 78 laboratories in nine countries revealed an overall rate ofbeta-lactamase production in 9 1 % of isolates.20 The occurrence of beta-lactamase production was slightly higher in type b (10-5%) than in non-type b (8 6%) isolates. Resistance rates were highest in Spain.
Multiple resistance to three or more antibiotics was found in 1-5% of isolates. In the UK sequential surveys of H influenzae resistance have been performed since 1977, 2122 and have shown a steady rise in the prevalence of strains resistant to antibiotics traditionally used to treat H influenzae infection. The latest survey in 1991 showed that beta-lactamase was produced by 21 % of type b isolates and 8-3% ofnon-type b isolates. Non-beta-lactamase ampicillin resistance was present in 5-8%. Overall, of 2212 isolates 14A4% were ampicillin resistant. Trimethoprim resistance was present in 6&8% of isolates. In a separate study resistance to cefaclor was found in 5-2% of 1272 isolates'6; ampicillin resistance can be associated with cross resistance to cephalosporins. H influenzae is generally sensitive to quinolones but there have been case reports ofciprofloxacin resistance.23 Multiple drug resistance is still rare.
Resistance probably emerges in the same way as penicillin resistance in S pneumoniae. H influenzae is present in nasopharyngeal flora and is also carried in sputum from chronic sputum producers. Treatment with antibiotics results in the appearance of resistant strains at these sites24 and spread between close contacts can then occur.25
Most H influenzae infections can be treated with amoxycillin or co-amoxiclav. If necessary, cephalosporins or a quinolone may be used. Erythromycin is generally not active against this species but other macrolides such as clarithromycin and azithromycin are more effective.
Moraxella (Branhamella) catarrhalis M catarrhalis now has a recognised place in the list of respiratory tract pathogens. In the early 1970s this species was sensitive to all antibiotics used to treat respiratory infections, but antibiotic resistance developed rapidly in the subsequent decade. In the USA beta-lactamase production was present in 75% of isolates by 1980.26 Two different beta-lactamases are produced, designated BRO-1 and BRO-2. These are encoded on chromosomal DNA but can be transferred between bacteria by conjugation, presumably on transposons. They are clinically significant because treatment failures occur when penicillins are used. However, they are very susceptible to beta-lactamase inhibitors such as clavulanic acid and sulbactam and are therefore sensitive to antibiotics such as co-amoxiclav. M catarrhalis retains some susceptibility to cephalosporins but, in addition to penicillins, resistance has been reported to a number of other antibiotics including trimethoprim, tetracycline, erythromycin, and aminoglycosides. Trimethoprim resistance is almost universal amongst isolates and the mechanism of this resistance is not understood. 
